| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $21,044,134 ) (Continued on the next page) |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K99DK140526 | Pancreatic beta-cell glucose toxicity and mRNA translation | 000 | 2 | NIH | 8/12/2025 | $90,000 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 004 | 7 | NIH | 7/14/2025 | $34,285 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 004 | 7 | NIH | 7/14/2025 | $141,429 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 002 | 3 | NIH | 2/28/2025 | $994,789 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01NS135175 | Modulating the adaptive immune response to enhance the efficiency of in vivo gene editing in muscle | 000 | 2 | NIH | 5/30/2025 | $537,378 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK137518 | Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering | 000 | 3 | NIH | 7/9/2025 | $715,307 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK131061 | Causal connections between axon guidance proteins and early progressive kidney function decline in diabetes | 000 | 4 | NIH | 3/31/2025 | $611,231 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK133528 | Dissecting the thermogenic adipose niche | 000 | 4 | NIH | 8/11/2025 | $701,614 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129850 | Gut microbial fermentation products of muscle-derived lactate as mediators of exercise and metabolism | 000 | 4 | NIH | 4/17/2025 | $593,332 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 000 | 4 | NIH | 11/15/2024 | $811,054 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161864 | Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes | 000 | 4 | NIH | 12/25/2024 | $758,888 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132469 | Transcriptional and epigenetic regulation of thermogenic adipocyte program | 000 | 4 | NIH | 4/17/2025 | $602,295 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HD117197 | Maternal exercise during lactation to ignite infant metabolism | 000 | 1 | NIH | 4/22/2025 | $657,909 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132535 | Elucidating and targeting beta-cell senescence and its SASP | 000 | 4 | NIH | 4/25/2025 | $427,500 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK099511 | Novel Mechanisms of Exercise Training Effects on Glucose Homeostasis | 002 | 11 | NIH | 5/28/2025 | $73,061 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK099511 | Novel Mechanisms of Exercise Training Effects on Glucose Homeostasis | 001 | 11 | NIH | 1/9/2025 | $657,554 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 002 | 9 | NIH | 9/9/2025 | $517,097 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK101043 | Exercise Regulation of Glucose Homeostasis | 002 | 27 | NIH | 5/14/2025 | $70,004 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK101043 | Exercise Regulation of Glucose Homeostasis | 001 | 27 | NIH | 2/20/2025 | $630,037 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK082659 | Developmental genes, miRNAs and adipose tissue | 000 | 17 | NIH | 5/8/2025 | $701,100 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK067536 | Role of IGF-1 and insulin receptors beta-cell survival | 002 | 18 | NIH | 5/16/2025 | $124,961 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK067536 | Role of IGF-1 and insulin receptors beta-cell survival | 001 | 18 | NIH | 11/15/2024 | $587,021 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK142331 | Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes | 001 | 2 | NIH | 7/3/2025 | $1,020,124 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | P30DK036836 | Diabetes Research Center | 001 | 39 | NIH | 6/30/2025 | $1,706,072 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK140790 | Identifying Targets for Preventing Neurocognitive Complications in Youth with T1D | 000 | 2 | NIH | 7/2/2025 | $631,348 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01AG054215 | Homeostasis functions of SKN-1A/Nrf1 | 001 | 8 | NIH | 7/10/2025 | $514,743 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | F99AG088573 | Insulin regulates aging-associated genes through chromatin topology | 000 | 2 | NIH | 8/27/2025 | $36,617 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK138605 | Translational Programming of Beta-cells in Response to Glucose Toxicity | 000 | 2 | NIH | 5/14/2025 | $707,452 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK137511 | Lipotoxicity and Maintenance of Metabolic Health | 000 | 3 | NIH | 4/23/2025 | $594,765 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K23DK134877 | Precision Monitoring: Understanding Momentary Affect, Glucose, and Self-care Behaviors in Adolescents and Young Adults with type 1 diabetes | 000 | 3 | NIH | 7/16/2025 | $190,239 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK128429 | Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin Resistance | 000 | 5 | NIH | 7/21/2025 | $592,643 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01AG096437 | Evaluating clinical and pathological markers of cognitive decline and Alzheimer's dementia in long-duration type 1 diabetes. | 000 | 1 | NIH | 9/8/2025 | $645,002 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K23DK137024 | Development of an intervention to target diabetes device use through an identity framework: ACCPTech (Adapt and Commit to CGM and Pump Technology) | 001 | 2 | NIH | 5/26/2025 | $0 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K23DK137024 | Development of an intervention to target diabetes device use through an identity framework: ACCPTech (Adapt and Commit to CGM and Pump Technology) | 000 | 2 | NIH | 2/19/2025 | $188,784 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R25DK140752 | Joslin-BIDMC Postbac Program in Diabetes and Metabolism | 000 | 2 | NIH | 8/21/2025 | $390,270 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK135095 | Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk | 000 | 4 | NIH | 8/12/2025 | $882,433 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 004 | 7 | NIH | 7/14/2025 | $41,667 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | RC2DK139552 | Epitranscriptomics in human obesity and type 2 diabetes | 000 | 2 | NIH | 8/22/2025 | $1,972,780 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 002 | 5 | NIH | 4/1/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 002 | 5 | NIH | 4/1/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 001 | 2 | NIH | 2/14/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 000 | 2 | NIH | 11/13/2024 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129479 | Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D | 000 | 4 | NIH | 7/31/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK120445 | Functional Validation of Gene Modifications that Protect Beta Cells against Autoimmunity Identified by Genome-Wide CRISPR Cas9 Screening | 000 | 6 | NIH | 7/1/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 001 | 8 | NIH | 8/27/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 000 | 8 | NIH | 11/15/2024 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK142331 | Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes | 000 | 1 | NIH | 4/22/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK126799 | Development of Prognostic Algorithms to Identify Subjects at High Risk of ESKD in Type 2 Diabetes | 000 | 4 | NIH | 8/19/2025 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | P30DK036836 | Diabetes Research Center | 000 | 38 | NIH | 12/6/2024 | $0 |
|
